Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome

Hormone Research

Volumn 68, Issue 2, 2007, Pages 83-90

  Crino A ^a   Di Giorgio, G ^a   Manco, M ^a   Grugni, G ^b   Maggioni, A ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Glucose metabolism; Growth hormone therapy; Insulin resistance; Insulin sensitivity; Prader Willi syndrome

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN;

AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRADER WILLI SYNDROME; PREPUBERTY; PRIORITY JOURNAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HEALTH STATUS INDICATORS; HUMAN GROWTH HORMONE; HUMANS; INFANT; INSULIN RESISTANCE; MALE; OBESITY; PRADER-WILLI SYNDROME; PUBERTY; RETROSPECTIVE STUDIES;

EID: 34347374478     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100371     Document Type: Article

References (42)

1. Ledbetter DH, Riccardi VM, Airhart SD, Strobel RJ, Keenan SB, Crawford JD: Deletions of chromosome 15 as a cause of Prader-Willi syndrome. N Engl J Med 1981;304:325-329.
2. Nicholls RD, Knoll JHM, Butler MG, Karam S, Lalande M: Genetic imprinting suggested by maternal heterodysomy in non-deletion Prader-Willi syndrome. Nature 1989;342:281-284.
3. Whittington JE, Holand AJ, Webb T, Butler J, Clarke D, Boer H: Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001;38:792-798.
4. Eiholzer E, Gisin R, Weinmann C, Kriemler S, Steinert H, Torresani T, Zachmann M, Prader A: Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 1998;157:368-377.
5. Eiholzer U, Bachmann S, l'Alemand D: Is there growth hormone deficiency in Prader-Willi syndrome? Horm Res 2000;53(suppl 3):44-52
6. Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M: GH secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996;9:393-400.
7. Thacker MJ, Hainline B, Dennis-Feezle LS, Johnson NB, Pescovitz OH: Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998;49:216-220.
8. Cappa M, Raguso G, Palmiotto T, Faedda A, Gurreri F, Neri G, Degenghi R, Loche S: The growth hormone response to hexarelin in patients with Prader-Willi Syndrome. J Endocrinol Invest 1998;21:501-505.
9. Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F: Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin Endocrinol 1998;48:769-775.
10. Corrias A, Bellone J, Beccaria L, Bosio L, Trifiro G, Livieri C, Ragusa L, Salvatoni A, Andreo M, Ciampalini P, Tonini G, Crino A: GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000;23:84-89.
11. Williams T, Berelowitz M, Joffe SN, Thorner MO, River J, Vale W, Frohman LA: Impaired growth hormone response to growth hormone releasing factor in obesity. New Engl J Med 1984;311:1403-1407.
12. Davies PSW, Evans S, Broomhead S, Clough H, Day JME, Laidlaw A, Barnes ND: The effect of growth hormone on height, weight and body composition in children with Prader-Willi syndrome. Arch Dis Child 1998;78:474-476.
13. Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzen EM: Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 1998;87:28-31.
14. Carrel AL, Myers SE, Whitman BY, Allen DB: Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999;134:215-221.
15. Lindgren AC, Hellstrom LG, Ritzen EM, Milerad J: Growth hormone treatment increases CO2 response, ventilation and central inspiratory drive in children with Prader-Willi syndrome. Eur J Pediatr 1999;158:936-940.
16. Whitman BY, Myers S, Carrel A, Allen D: The behavioural impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study. Pediatrics 2002;109:E35.
17. Cassidy SB: Prader-Willi syndrome. Curr Probl Pediatr 1984;14:1-55.
18. Schuster DP, Osei K, Zipf WB: Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 1996;45:1514-1520.
19. Talebizadeh Z, Butler MG: Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects. Clin Genet 2004;67:230-239.
20. Fowelin J, Attvall S, Von-Schenck H, Smith U, Lager I: Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 1991;34:500-506.
21. Bak JF, Moller N, Schimitz O: Effect of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. Am J Physiol 1991;260:736-742.
22. Tauber M, Baurbeau C, Jouret B, Pienkowski C, Malzac P, Moncla A, Rochiccioli P: Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children. Horm Res 2000;53:279-287.
23. Lindgren AC, Ritzén EM: Five years of growth hormone treatment in children with Prader-Willi syndrome. In collaboration with the Swedish National Growth Hormone Advisory Group. Acta Paediatr 1999;433:109-111.
24. Lindgren AC, Hagenäs L, Ritzén EM: In collaboration with the Swedish National Growth Hormone Advisory Group. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Horm Res 1999;51:157-161.
25. l'Allemand D, Eiholzer U, Schlumpf M, Torresani T, Girard J: Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome. Horm Res 2003;59:239-248
26. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F: Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993;91:398-402.
27. GH Research Society: Consensus Guidelines for Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society. J Clin Endocrinol Metab 2000;85:3990-3993.
28. Dammacco F, Boghen MF, Camanni F, Cappa M, Ferrari C, Ghigo E, Giordano G, Loche S, Minuto F, Mucci M, Muller EE and The Italian Collaborative Group of Neuroendocrinology: Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. J Clin Endocrinol Metab 1993;77:68-72.
29. WHO: Consultation on Definition Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of WHO Consultation. Geneva, World Health Organization, 1999, pp 1-49.
30. Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, Polonsky KS: Plasma insulin, C-peptide, and proinsulin concentrations in obese and non obese individuals with varing degrees of glucose tolerance. J Clin Endocrinol Metab 1993;76:44-48.
31. Dietz WH, Robinson TN: Use of body mass index (BMI) as a measure of overweight in children and adolescents. J Pediatr 1998;132:191-193.
32. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.
33. Katz A, Nambi SS, Mather K, Baron AD, Follman DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
34. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L: Detection of insulin resistance by simple quantitative insulin sensitivity index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002;87:144-147.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell functions from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
36. Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A: Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi Syndrome. Eur J Pediatr 1998;157:890-893.
37. Eiholzer U: in Savage MO (ed): Prader Willi Syndrome: Effects of Human Growth Hormone Treatment - Endocrine Development. Basel, S. Karger AG, vol 3, 2001.
38. Husbands S, Ongk KL, Gilbert J, Wass JAH, Dunger DB: Increased insulin sensitivity in young, growth hormone deficient children. Clin Endocrinol 2000;55:87-92.
39. Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA: Growth hormone-deficient adults are insulin-resistant. Metabolism 1995;44:1126-1129.
40. Nørrelund H, Vahl N, Juul A, Møller N, Alberti KGMM, SkakkebÆNE, Christiansen JS, Jørgennsen JOL: Continuation of growth hormone therapy (GH) in GH-deficient patients during transition from childhood to adulthood. Impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 2000;85:1912-1917.
41. Höbye C, Frystyk J, Thorén M: The growth hormone-insulin-like growth factor axis in adult patients with Prader-Willi syndrome. Growth Horm IGF Res 2003;13:269-274.
42. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Wikland KA, Ranke MB, Price DA, on behalf of the KIGS International Board: Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth database). Clin Endocrinol 2006;65:178-185.